##  [Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine](/us-en/news/media-releases/novartis-announces-five-year-data-reinforce-safety-and-efficacy-profile-aimovig-erenumab-aooe-adult-patients-episodic-migraine-0 "Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine") 

  Oct 03, 2020